BRPI1015147A2 - métodos para melhorar a farmacocinética - Google Patents

métodos para melhorar a farmacocinética

Info

Publication number
BRPI1015147A2
BRPI1015147A2 BRPI1015147A BRPI1015147A BRPI1015147A2 BR PI1015147 A2 BRPI1015147 A2 BR PI1015147A2 BR PI1015147 A BRPI1015147 A BR PI1015147A BR PI1015147 A BRPI1015147 A BR PI1015147A BR PI1015147 A2 BRPI1015147 A2 BR PI1015147A2
Authority
BR
Brazil
Prior art keywords
methods
improve pharmacokinetics
pharmacokinetics
improve
Prior art date
Application number
BRPI1015147A
Other languages
English (en)
Inventor
Q Tran Jonathan
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of BRPI1015147A2 publication Critical patent/BRPI1015147A2/pt
Publication of BRPI1015147B1 publication Critical patent/BRPI1015147B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
BRPI1015147-8A 2009-04-25 2010-04-22 Formulação farmacêutica, uso da formulação farmacêutica, composição farmacêutica, uso de r7227 e um inibidor da citocromo p450 mono-oxigenase, kit, e, conjunto embalado farmacêutico BRPI1015147B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17272209P 2009-04-25 2009-04-25
US61/172,722 2009-04-25
PCT/EP2010/055317 WO2010122087A1 (en) 2009-04-25 2010-04-22 Methods for improving pharmacokinetics

Publications (2)

Publication Number Publication Date
BRPI1015147A2 true BRPI1015147A2 (pt) 2018-01-30
BRPI1015147B1 BRPI1015147B1 (pt) 2022-03-08

Family

ID=42236685

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1015147-8A BRPI1015147B1 (pt) 2009-04-25 2010-04-22 Formulação farmacêutica, uso da formulação farmacêutica, composição farmacêutica, uso de r7227 e um inibidor da citocromo p450 mono-oxigenase, kit, e, conjunto embalado farmacêutico

Country Status (36)

Country Link
US (4) US20100272682A1 (pt)
EP (1) EP2421527B1 (pt)
JP (1) JP5523552B2 (pt)
KR (1) KR101471238B1 (pt)
CN (2) CN105233249A (pt)
AR (1) AR076388A1 (pt)
AU (1) AU2010240893B2 (pt)
BR (1) BRPI1015147B1 (pt)
CA (1) CA2758644C (pt)
CL (1) CL2011002643A1 (pt)
CO (1) CO6440593A2 (pt)
CR (1) CR20110551A (pt)
DK (1) DK2421527T3 (pt)
EC (1) ECSP11011420A (pt)
ES (1) ES2683736T3 (pt)
HK (1) HK1215858A1 (pt)
HR (1) HRP20181306T1 (pt)
HU (1) HUE040182T2 (pt)
IL (1) IL215620A (pt)
LT (1) LT2421527T (pt)
MA (1) MA33212B1 (pt)
MX (2) MX2011011105A (pt)
MY (1) MY169734A (pt)
NZ (1) NZ595917A (pt)
PE (1) PE20120638A1 (pt)
PL (1) PL2421527T3 (pt)
PT (1) PT2421527T (pt)
RS (1) RS57501B1 (pt)
RU (1) RU2591830C2 (pt)
SG (1) SG175328A1 (pt)
SI (1) SI2421527T1 (pt)
TR (1) TR201809600T4 (pt)
TW (1) TWI468160B (pt)
UA (1) UA103801C2 (pt)
WO (1) WO2010122087A1 (pt)
ZA (1) ZA201107421B (pt)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2009303483A1 (en) * 2008-10-15 2010-04-22 Intermune, Inc. Therapeutic antiviral peptides
AR075584A1 (es) 2009-02-27 2011-04-20 Intermune Inc COMPOSICIONES TERAPEUTICAS QUE COMPRENDEN beta-D-2'-DESOXI-2'-FLUORO-2'-C-METILCITIDINA Y UN DERIVADO DE ACIDO ISOINDOL CARBOXILICO Y SUS USOS. COMPUESTO.
EP2455068A1 (en) * 2010-11-09 2012-05-23 F. Hoffmann-La Roche AG Pharmaceutical composition for treating HCV infections
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
WO2013059638A1 (en) 2011-10-21 2013-04-25 Abbvie Inc. Combination treatment (eg. with abt-072 or abt -333) of daas for use in treating hcv
CN103826627B (zh) 2011-10-21 2016-02-24 艾伯维公司 包含至少两种直接抗病毒剂和利巴韦林的组合物在制备治疗hcv的药物中的用途
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
JP6038179B2 (ja) 2012-01-11 2016-12-07 アッヴィ・インコーポレイテッド Ｈｃｖプロテアーゼ阻害剤の製造方法
JP2015522022A (ja) * 2012-06-27 2015-08-03 アッヴィ・インコーポレイテッド Ｈｃｖの処置に使用するためのａｂｔ−４５０およびリトナビルおよび例えばａｂｔ−０７２および／またはａｂｔ−３３３の併用処置
JP2015533124A (ja) 2012-10-08 2015-11-19 アッヴィ・インコーポレイテッド Ｈｃｖプロテアーゼ阻害剤を作製するのに有用な化合物
CN106535895B (zh) * 2014-05-01 2020-02-28 艾格尔峰生物制药有限公司 丁型肝炎病毒感染的治疗
US10076512B2 (en) 2014-05-01 2018-09-18 Eiger Biopharmaceuticals, Inc. Treatment of hepatitis delta virus infection
US11311519B2 (en) 2014-05-01 2022-04-26 Eiger Biopharmaceuticals, Inc. Treatment of hepatitis delta virus infection
EP3285768B1 (en) 2015-04-21 2020-12-30 Eiger Biopharmaceuticals, Inc. Pharmaceutical compositions comprising lonafarnib and ritonavir
JP7129703B2 (ja) 2016-04-28 2022-09-02 エモリー ユニバーシティー アルキン含有ヌクレオチド及びヌクレオシド治療組成物並びにそれらに関連した使用
CN117105928B (zh) * 2023-08-22 2024-03-26 上海蓝木化工有限公司 一种蛋白酶抑制剂及其制备方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100333016B1 (ko) 1992-12-29 2002-11-22 아보트 러보러터리즈 레트로바이러스성프로테아제억제화합물,이의제조방법및이를함유하는약제학적조성물
IL110752A (en) 1993-09-13 2000-07-26 Abbott Lab Liquid semi-solid or solid pharmaceutical composition for an HIV protease inhibitor
US5559158A (en) 1993-10-01 1996-09-24 Abbott Laboratories Pharmaceutical composition
IL111991A (en) 1994-01-28 2000-07-26 Abbott Lab Liquid pharmaceutical composition of HIV protease inhibitors in organic solvent
US6037157A (en) * 1995-06-29 2000-03-14 Abbott Laboratories Method for improving pharmacokinetics
IL141438A0 (en) 2000-02-23 2002-03-10 Pfizer Prod Inc Method of increasing the bioavailability and tissue penetration of azithromycin
EP1303487A4 (en) * 2000-07-21 2005-11-23 Schering Corp NOVEL PEPTIDES AS INHIBITORS OF THE NS3 SERINE PROTEASE OF HEPATITIS C VIRUS
NZ541187A (en) 2002-12-16 2007-12-21 Boehringer Ingelheim Int Use of a combination containing a non-nucleoside reverse transcriptase inhibitor (NNRTI) with an inhibitor of cytochrome P450, such as protease inhibitors
SI1677827T1 (sl) * 2003-10-27 2009-06-30 Vertex Pharma Zdravilni sestavek proti virusu hepatitisa c (hcv)
WO2008033466A2 (en) * 2006-09-14 2008-03-20 Combinatorx (Singapore) Pre. Ltd. Compositions and methods for treatment of viral diseases
US20120220520A1 (en) * 2006-10-17 2012-08-30 Van T Klooster Gerben Albert Eleutherius Bioavailable combinations for hcv treatment

Also Published As

Publication number Publication date
CR20110551A (es) 2011-12-13
BRPI1015147B1 (pt) 2022-03-08
MA33212B1 (fr) 2012-04-02
EP2421527A1 (en) 2012-02-29
IL215620A0 (en) 2012-01-31
AU2010240893A1 (en) 2011-11-03
TW201041582A (en) 2010-12-01
US20180318267A1 (en) 2018-11-08
RU2011142651A (ru) 2013-05-27
PE20120638A1 (es) 2012-05-26
TR201809600T4 (tr) 2018-07-23
SG175328A1 (en) 2011-11-28
CA2758644C (en) 2018-01-09
MX2011011105A (es) 2011-11-18
CN105233249A (zh) 2016-01-13
KR101471238B1 (ko) 2014-12-12
JP2012524753A (ja) 2012-10-18
US20100272682A1 (en) 2010-10-28
MX351185B (es) 2017-10-04
CO6440593A2 (es) 2012-05-15
AR076388A1 (es) 2011-06-08
KR20120014170A (ko) 2012-02-16
CL2011002643A1 (es) 2012-05-25
ZA201107421B (en) 2022-11-30
MY169734A (en) 2019-05-14
UA103801C2 (ru) 2013-11-25
PL2421527T3 (pl) 2018-10-31
US20200230112A1 (en) 2020-07-23
ECSP11011420A (es) 2011-11-30
HK1215858A1 (zh) 2016-09-23
WO2010122087A1 (en) 2010-10-28
NZ595917A (en) 2014-02-28
SI2421527T1 (sl) 2018-09-28
US20170119739A1 (en) 2017-05-04
EP2421527B1 (en) 2018-06-13
LT2421527T (lt) 2018-09-10
IL215620A (en) 2015-10-29
PT2421527T (pt) 2018-08-02
HUE040182T2 (hu) 2019-02-28
CN102413827A (zh) 2012-04-11
HRP20181306T1 (hr) 2018-10-19
RU2591830C2 (ru) 2016-07-20
DK2421527T3 (en) 2018-08-13
AU2010240893B2 (en) 2015-02-05
CA2758644A1 (en) 2010-10-28
TWI468160B (zh) 2015-01-11
JP5523552B2 (ja) 2014-06-18
US10918626B2 (en) 2021-02-16
RS57501B1 (sr) 2018-10-31
ES2683736T3 (es) 2018-09-27

Similar Documents

Publication Publication Date Title
BRPI1015147A2 (pt) métodos para melhorar a farmacocinética
BRPI1015166A2 (pt) método para usar um catalisador
CU24162B1 (es) Derivados 5-aril-1,2,4-triazolona ligada a bisarilo sustituidos
BRPI1013482A2 (pt) método para produzir um composto
BRPI1007160A2 (pt) Método para esterilizar um material
BRPI1015444A2 (pt) método para produzir (+)-zizaeno
BR112012000657A2 (pt) novos azabicilohexanos
BRPI1014267A2 (pt) processo para a carbonitrificação
BR112012022525A2 (pt) método para produzir butanol
NO20101649A1 (no) Paravane med en syvende bridleline
BRPI1008308A2 (pt) processo para produzir um composto
FR2946241B1 (fr) Zesteur a savon
BR112012016099A2 (pt) método para formar um substrato
BR112013014951A2 (pt) selos
IT1396671B1 (it) Scambiatore a microcanali
NO20091602L (no) Energigjenvinning
BRPI0821058A2 (pt) Produto para melhorar a fotossíntese
BR112013015002A2 (pt) método para obter um composto
BR112012000579A2 (pt) método para conclusão do poço
BR112013009662A2 (pt) forma para fazer estruturas
DK2466722T3 (da) Åg til en permamagnetmaskine
FR2959257B3 (fr) Store a banne
BRPI1009638A2 (pt) processo para produzir um hidrocarboneto
FI20095440A (fi) Muodostusosa
DE102009060754A8 (de) Hydraulische Anordnung

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]

Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO EM FUNCAO DA REVOGACAO DO ART. 229-C DA LEI NO 9.279, DE 1996, POR FORCA DA LEI NO 14.195, DE 2021

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 22/04/2010, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO.